Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent Deferred Tax AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
LeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetReceivables - Other
Ratios

Ascentage Pharma Group International (AAPG) Receivables - Net (2023 - 2025)

Ascentage Pharma Group International posted quarterly Receivables - Net of $35.7 million for Q4 2025, up 208.1% year-on-year from $11.6 million in Q4 2024, and up 226.01% on a QoQ basis from $10.9 million in Q2 2025.

Ascentage Pharma Group International (AAPG) has 3 years of Receivables - Net data on file, last reported at $35.7 million in Q4 2025.

  • For the quarter ending Q4 2025, Receivables - Net rose 208.1% year-over-year to $35.7 million; the trailing twelve-month figure through Dec 2025 stood at $35.7 million (up 208.1% YoY), and the FY2025 full-year result was $36.2 million, up 217.56% from the prior year.
  • Receivables - Net for Q4 2025 stood at $35.7 million, up from $10.9 million in the prior quarter.
  • Across five years, Receivables - Net topped out at $35.7 million in Q4 2025 and bottomed at $10.9 million in Q2 2025.
  • The 3-year median for Receivables - Net is $15.9 million (2023), against an average of $19.6 million.
  • The widest annual swing landed in 2024, when Receivables - Net sank 42.88%; it then surged 208.1% in 2025.
  • A 3-year view of Receivables - Net shows it stood at $20.3 million in 2023, then plunged by 42.88% to $11.6 million in 2024, then soared by 208.1% to $35.7 million in 2025.
  • The last three Receivables - Net figures came in at $35.7 million (Q4 2025), $10.9 million (Q2 2025), and $11.6 million (Q4 2024), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 1,638,563.89 Bn 1,638,563.89 Bn -
2 Alterity Therapeutics 767,934.24 Bn 767,934.20 Bn -
3 Legend Biotech 2,937.00 Bn 2,936.10 Bn 242.10 Mn
4 Nanobiotix 2,282.79 Bn 2,282.72 Bn -
5 Akari Therapeutics 2,169.69 Bn 2,169.69 Bn -
6 Vertex Pharmaceuticals 110.41 Bn 103.16 Bn 2.59 Bn
7 Regeneron Pharmaceuticals 66.44 Bn 57.69 Bn 3.31 Bn
8 Evaxion A 65.44 Bn 65.42 Bn -
9 Alnylam Pharmaceuticals 39.53 Bn 36.52 Bn 959.66 Mn
10 Ascentage Pharma Group International 1.11 Bn 937.28 Mn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 35.66 Mn
Dec 31, 2025 35.66 Mn
Jun 30, 2025 10.94 Mn
Jun 30, 2025 10.94 Mn
Dec 31, 2024 11.57 Mn
Dec 31, 2024 11.57 Mn
Dec 31, 2023 20.26 Mn
Dec 31, 2023 20.26 Mn